Gene therapy maker Sarepta tells FDA it won't halt shipments despite
patient deaths
[July 21, 2025]
By MATTHEW PERRONE
WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it
won't comply with a request from the Food and Drug Administration to
halt all shipments of its gene therapy following the death of a third
patient receiving one of its treatments for muscular dystrophy.
The highly unusual move is a latest in a string of events that have
hammered the company's stock for weeks and recently forced it to lay off
500 employees. The company's decision not to comply with the FDA also
places future availability of its leading therapy, called Elevidys, in
doubt.
The FDA said in a statement Friday night that officials met with Sarepta
and requested it suspend all sales but “the company refused to do so.”
The agency has the authority to pull drugs from the market, but the
cumbersome regulatory process can take months or even years. Instead,
the agency usually makes an informal request and companies almost always
comply.
“We believe in access to drugs for unmet medical needs but are not
afraid to take immediate action when a serious safety signal emerges,”
FDA Commissioner Marty Makary said in a statement.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's
muscular dystrophy, the fatal muscle-wasting disease that affects males,
though it has faced scrutiny since its clearance in 2023. The one-time
treatment received accelerated approval against the recommendations of
some FDA scientists who doubted its effectiveness.
The FDA granted full approval last year and expanded the therapy’s use
to patients 4 years and older, including those who can no longer walk.
Previously, it was only available for younger patients who were still
walking.
Sarepta said Friday that its scientific review showed “no new or changed
safety signals” for younger patients with Duchenne’s who have earlier
stages of the disease. The company said it plans to keep the drug
available for those patients.
“We look forward to continued discussions and sharing of information
with FDA,” the company said in a statement.
[to top of second column]
|
The Food and Drug Administration seal is seen at the Hubert Humphrey
Building Auditorium in Washington, Tuesday, April 22, 2025. (AP
Photo/Jose Luis Magana, File)
 Sarepta halted shipments last month
of the therapy for older boys with Duchenne’s, which gradually
destroys muscle and skeletal strength, resulting in early death. The
move followed the deaths of two teenage boys taking the therapy.
The company also confirmed a third death Friday: a
51-year-old patient who was taking an experimental gene therapy in a
trial for a different form of muscular dystrophy. Sarepta said it
reported the death to the FDA on June 20. The FDA said Friday it
placed that trial on hold.
Sarepta noted that the gene therapy involved in the incident uses “a
different dose and is manufactured using a different process,” than
Elevidys.
All three patient deaths were linked to liver injury, a side effect
noted in Sarepta's prescribing information.
Earlier this week Sarepta announced it would add a bold warning to
drug and lay off a third of its employees. The company did not
mention the third patient death in its news release or conference
call announcing those changes, sparking pointed criticism from Wall
Street analysts.
Company shares fell more than 35% Friday to close at $14.07.
Cambridge, Massachusetts-based Sarepta has received FDA approval for
three other Duchenne’s drugs since 2016, none of which have been
confirmed to work. The company has long been criticized for failing
to complete several studies needed to secure full FDA approval of
its drugs.
All contents © copyright 2025 Associated Press. All rights reserved
 |
